Eisai, Purdue To File Insomnia Drug Following Positive Head-To-Head

Eisai and its partner Purdue are expected to file insomnia drug lemborexant with the US FDA within the next 12 months, following more positive data.

Moon
Eisai and Purdue's insomnia drug advances • Source: Shutterstock

Eisai Co. Ltd. and Purdue Pharma LP have reported positive Phase III data for their insomnia therapy lemborexant from the SUNRISE 1 trial; the drug appears to impact an underlying reason for a patient’s inability to sleep well.

Discovered by Eisai, lemborexant is being jointly developed by Eisai and Purdue as a treatment for insomnia under a 2015...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Clinical Trials

More from R&D